Ironwood Pharmaceuticals Inc Class A IRWD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Trading Information
- Previous Close Price
- $4.85
- Day Range
- $4.80–4.87
- 52-Week Range
- $2.96–5.76
- Bid/Ask
- $4.80 / $4.81
- Shares Outstanding
- 165.55M
- Market Cap
- $798.78M
- Volume/Avg
- 172,296 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 6.13
- Price/Sales
- 1.98
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 100
Valuation
Metric | IRWD |
|---|---|
Price/Earnings (Normalized) | 6.13 |
Price/Book Value | — |
Price/Sales | 1.98 |
Price/Cash Flow | 3.60 |
Price/Earnings
IRWD
Financial Strength
Metric | IRWD |
|---|---|
Quick Ratio | 6.31 |
Current Ratio | 6.51 |
Interest Coverage | 8.28 |
Quick Ratio
IRWD
Profitability
Metric | IRWD |
|---|---|
Return on Assets (Normalized) | 41.65% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 54.69% |
Return on Assets
IRWD
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|k!#zM!&d | LOCK|y?>Y | $71B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|<#&!p#? | LOCK|lmgv$ | $51B | |||
| Haleon PLC ADR HLN | LOCK|#%Lb!q | LOCK|!P | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|!D$vFQ%$ | LOCK|P@ | $34B | |||
| Viatris Inc VTRS | LOCK|bTkS$^ | LOCK|kp | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|Gh^ | LOCK|<B | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|!?$rdd | LOCK|^%# | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|>$<V%g | LOCK|!f< | $5B | |||
| Perrigo Co PLC PRGO | LOCK|X<TRBh | LOCK|^Bq | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|lnc^&jM | LOCK|yX@l | $2B |
United States